Rankings
▼
Calendar
NAGE
Niagen Bioscience Inc
$423M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$29M
+37.4% YoY
Gross Profit
$18M
62.5% margin
Operating Income
$7M
24.4% margin
Net Income
$7M
24.6% margin
EPS (Diluted)
$0.09
QoQ Revenue Growth
+13.9%
Cash Flow
Operating Cash Flow
$9M
Free Cash Flow
$9M
Stock-Based Comp.
$752,000
Balance Sheet
Total Assets
$68M
Total Liabilities
$22M
Stockholders' Equity
$46M
Cash & Equivalents
$45M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$29M
$21M
+37.4%
Gross Profit
$18M
$13M
+40.7%
Operating Income
$7M
-$168,000
+4332.7%
Net Income
$7M
$114,000
+6197.4%
← FY 2024
All Quarters
Q1 2025 →
NAGE Q4 2024 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena